Parul believes that government ’ s policy and funding support has also been an enabler in driving the fast-paced growth of the biotech sector .
“ Startups are going to play a major role in the near future to help India attain its goal of selfreliance . One major aspect that will further drive the growth of the startup ecosystem is constructive engagement between the different stakeholdersacademia , industry , venture capitalists and drug regulators . A policy push streamlining innovation commercialization will additionally assist in the advancement of the biotech sector , which attracts far less investment compared to other technology sectors such as the
“
IT ,” mentions Parul .
We intend to remove the fear and stigma that is often associated with skin diseases .
Way Forward
Vitiligo treatment is an unmet need with a huge market opportunity of over USD 2 billion . Currently , immunomodulators form a major proportion of this market . The company aspires to replace these with its targeted and safe topical treatment .
Ahammune recently raised an undisclosed amount of funding from various investors .
“ Drug discovery is a capital intensive process . Our Pre-Series A funding helped us tremendously to complete our pre-clinical studies and now start our human studies . We will be starting our next fund raise soon ,” adds Parul .
While advancing its therapeutic portfolio for vitiligo through multiple stages of human clinical trials , Ahammune plans to continue with expansion of its scientific breakthroughs through development of new and comprehensive treatment strategies for other dermatological diseases .
Outlining the future priorities , Parul says , “ We aim to introduce our drug into the Indian market first while simultaneously developing it for the rest of the world . We intend to remove the fear and stigma that is often associated with skin diseases which remain unmet medical needs ."
BIOVOICENEWS . COM 19